Plus Therapeutics, GTC team up to add NGS to CNSide CSF platform

The collaboration aims to combine CNSide’s guideline-recognized CSF tumor cell enumeration with DNA and RNA profiling across hundreds of biomarkers from a single specimen.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.